A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...

Somchai, a Thai native, was 21 years old and faced a double threat to his long-term health and wellbeing. He was living with ...

A modelling study shows the six-monthly anti-HIV jab, lenacapavir, could end Aids in SA by 2032 — but only if between two and ...

In the latest trading session, Gilead Sciences (GILD) closed at $105.25, marking a +2% move from the previous day. The stock lagged the S&P 500's daily gain of 9.52%. Elsewhere, the Dow saw an upswing ...

On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional ...

Gilead legal chief, leaves Cytokinetics after 7 months as CLO. His exit comes as the biotech awaits FDA decision on a heart ...

Human immunodeficiency virus, if untreated, causes acquired immunodeficiency syndrome (AIDS), and death. HIV is almost entirely preventable by using condoms, or by taking PrEP drugs. PrEP drugs do not ...

While Gilead is eliminating 149 positions at its headquarters in Foster City, Roche is letting go of 108 workers at its ...

South Florida, an area with the highest rate of HIV/AIDS in the country, is already starting to feel the effects of the Trump ...

In people with HIV taking antiretroviral therapy, excessive visceral abdominal fat drives cardiovascular disease risk, even ...